STRN3: A Potential Drug Target and Biomarker for Stroke (G29966)

Target Name: STRN3

NCBI ID: G29966

STRN3: A Potential Drug Target and Biomarker for Stroke

Stroke is a leading cause of death and disability worldwide, affecting millions of people each year. Despite advances in treating stroke, the survival rate remains poor, and the recurrence rate is high. Therefore, there is a need for new treatments and better understanding of the underlying mechanisms to improve outcomes.

STRN3, a protein known as striatin-3, has been identified as a potential drug target and biomarker for stroke. Striatin-3 is a nuclear protein that is expressed in various tissues and plays a role in the regulation of cellular processes, including cell growth , apoptosis, and inflammation.

Recent studies have shown that Striatin-3 is involved in the regulation of blood-brain barrier (BBB) 鈥嬧?媐unction, which is critical for the delivery of therapeutic agents to the site of stroke. The BBB is a specialized barrier that separates the brain from the blood and plays a vital role in maintaining the integrity of the central nervous system (CNS).

STRN3 has been shown to regulate the expression of genes involved in the formation of the BBB, as well as its function. This suggests that Striatin-3 may be a useful target for drugs that are designed to improve BBB function and enhance the delivery of therapeutic agents to the site of stroke.

In addition to its potential as a drug target, Striatin-3 has also been shown to be a potential biomarker for stroke. The use of biomarkers, such as STRN3, can help doctors diagnose and monitor the progression of stroke more accurately.

Studies have shown that Striatin-3 is expressed in the brains of individuals with ischemic stroke, which is the most common type of stroke. In addition, individuals with basal spasticity, which is a type of non-ischemic stroke, also had increased levels of Striatin-3 in their brains.

Ischemic stroke, which is caused by a blockage of blood flow to the brain, is the most common form of stroke and is associated with the highest mortality rate. The recurrence rate of ischemic stroke is high, and the treatment options are limited. Therefore, there is a need for new treatments that can improve outcomes and reduce the recurrence rate.

STRN3 has been shown to be involved in the regulation of cellular processes that may be involved in the recurrence of ischemic stroke. For example, studies have shown that Striatin-3 can inhibit the activity of a protein called FAK, which is involved in the formation of blood-brain barrier cells that may contribute to the recurrence of ischemic stroke.

In addition, Striatin-3 has also been shown to regulate the expression of genes involved in the formation of glial cells, which are the support cells for the central nervous system. The recurrence of ischemic stroke is thought to involve the destruction of glial cells, and therefore

Protein Name: Striatin 3

Functions: Binds calmodulin in a calcium dependent manner. May function as scaffolding or signaling protein

More Common Targets